Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VR004 (apomorphine)
- Development stage
- Discontinued
- Lead developer
- Phillips-Medisize
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
VR004 is an inhaled dry powder formulation of apomorphine hydrochloride, a non-selective dopamine agonist, developed by Vectura Group for the treatment of erectile dysfunction. The drug is delivered to the lungs using the proprietary Aspirair dry powder inhaler, which facilitates rapid systemic absorption and a fast onset of action. Unlike phosphodiesterase 5 (PDE5) inhibitors that act peripherally, apomorphine acts centrally in the brain, specifically on the paraventricular nucleus of the hypothalamus, to trigger the erectile response. In Phase IIb clinical trials, VR004 demonstrated significant efficacy, with a majority of patients achieving erections suitable for intercourse within 5 to 10 minutes of dosing. Despite positive results, the program was discontinued after Vectura sought a commercial partner to progress the candidate into Phase III trials.
- Other names
- apomorphine hydrochloride
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)ADRA1D (α1D)ADRA2B (α2B)ADRA2C (α2C)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on VR004 (apomorphine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VR004 (apomorphine).